Key Points
- CEO Amir Heshmatpour bought 50,000 shares at an average $4.19 each, spending $209,500 and increasing his direct stake by 1.53% to 3.313 million shares.
- Neonc reported a quarterly loss of $0.28 per share, missing analysts’ expected loss of $0.25 per share. The stock was up 7.3% in the article’s report.
- Analyst views were mixed, but the consensus rating was Moderate Buy, with a stated average price target of $16.00.
Neonc Technologies Holdings, Inc. (NASDAQ:NTHI - Get Free Report) CEO Amir Heshmatpour purchased 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, November 11th. The stock was purchased at an average price of $4.25 per share, with a total value of $85,000.00. Following the purchase, the chief executive officer directly owned 3,333,000 shares of the company's stock, valued at $14,165,250. The trade was a 0.60% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Neonc Technologies Stock Up 7.3%
Shares of NASDAQ NTHI opened at $4.85 on Friday. The business has a 50-day moving average of $3.30 and a two-hundred day moving average of $5.29. Neonc Technologies Holdings, Inc. has a 1 year low of $2.50 and a 1 year high of $11.81.
Neonc Technologies (NASDAQ:NTHI - Get Free Report) last posted its earnings results on Thursday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by ($0.03).
Analyst Ratings Changes
A number of analysts have weighed in on the company. Roth Capital began coverage on Neonc Technologies in a research report on Thursday, September 24th. They set a "buy" rating for the company. Zacks Research raised Neonc Technologies from a "strong sell" rating to a "hold" rating in a report on Thursday, November 5th. Wall Street Zen upgraded Neonc Technologies from a "sell" rating to a "hold" rating in a research note on Saturday, November 7th. BTIG Research reaffirmed a "buy" rating and set a $15.00 price target on shares of Neonc Technologies in a report on Tuesday, September 8th. Finally, Weiss Ratings downgraded Neonc Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a report on Wednesday, October 21st. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Neonc Technologies has an average rating of "Moderate Buy" and an average price target of $16.00.
View Our Latest Research Report on Neonc Technologies
Institutional Investors Weigh In On Neonc Technologies
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE grew its stake in shares of Neonc Technologies by 5.0% during the 1st quarter. Bank of America Corp DE now owns 235,396 shares of the company's stock worth $1,650,000 after purchasing an additional 11,108 shares during the period. Westmount Partners LLC lifted its stake in shares of Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company's stock valued at $893,000 after purchasing an additional 153,858 shares during the period. BlackRock Inc. acquired a new stake in shares of Neonc Technologies in the second quarter valued at about $815,000. Finally, Global Retirement Partners LLC acquired a new stake in shares of Neonc Technologies in the second quarter valued at about $126,000.
About Neonc Technologies
(
Get Free Report)
NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company's pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
